MannKind Corporation (NASDAQ:MNKD) gapped up prior to trading on Friday . The stock had previously closed at $1.93, but opened at $1.98. MannKind Corporation shares last traded at $2.00, with a volume of 1,896,795 shares changing hands.

Several equities research analysts have recently commented on MNKD shares. Maxim Group restated a “buy” rating on shares of MannKind Corporation in a report on Friday, September 1st. J P Morgan Chase & Co restated a “sell” rating on shares of MannKind Corporation in a report on Thursday, May 11th. ValuEngine lowered shares of MannKind Corporation from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Piper Jaffray Companies set a $1.00 price target on shares of MannKind Corporation and gave the company a “sell” rating in a report on Thursday, May 11th. Finally, Zacks Investment Research lowered shares of MannKind Corporation from a “hold” rating to a “sell” rating in a report on Saturday, August 12th. Three analysts have rated the stock with a sell rating, one has issued a hold rating and one has given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $0.92.

The firm has a market capitalization of $207.27 million, a price-to-earnings ratio of 1.49 and a beta of 3.16. The company’s 50 day moving average is $1.44 and its 200-day moving average is $1.37.

MannKind Corporation (NASDAQ:MNKD) last posted its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.35) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by $0.10. MannKind Corporation had a net margin of 71.60% and a negative return on equity of 24.93%. The business had revenue of $2.16 million during the quarter, compared to analysts’ expectations of $2.75 million. During the same period in the previous year, the business posted $0.08 EPS. Equities research analysts expect that MannKind Corporation will post ($0.94) earnings per share for the current year.

Several hedge funds and other institutional investors have recently bought and sold shares of MNKD. Balyasny Asset Management LLC purchased a new position in shares of MannKind Corporation in the second quarter valued at approximately $568,000. LMR Partners LLP acquired a new stake in MannKind Corporation in the second quarter valued at approximately $352,000. KCG Holdings Inc. raised its holdings in MannKind Corporation by 268.0% in the first quarter. KCG Holdings Inc. now owns 147,952 shares of the biopharmaceutical company’s stock valued at $219,000 after acquiring an additional 107,752 shares in the last quarter. Finally, Harel Insurance Investments & Financial Services Ltd. raised its holdings in MannKind Corporation by 20.1% in the second quarter. Harel Insurance Investments & Financial Services Ltd. now owns 588,520 shares of the biopharmaceutical company’s stock valued at $830,000 after acquiring an additional 98,520 shares in the last quarter. 15.67% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This article was first posted by Daily Political and is the property of of Daily Political. If you are accessing this article on another site, it was illegally copied and reposted in violation of United States and international copyright legislation. The legal version of this article can be read at https://www.dailypolitical.com/2017/09/08/mannkind-corporation-mnkd-shares-gap-up-to-1-98.html.

MannKind Corporation Company Profile

MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control.